Search: WFRF:(Verheugt Freek W A) >
Percutaneous corona...
Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin : Insights from the ARISTOTLE trial
-
- Kopin, David (author)
- Duke University School of Medicine, Durham, USA
-
- Jones, W Schuyler (author)
- Duke University School of Medicine, Durham, USA
-
- Sherwood, Matthew W (author)
- Inova Heart and Vascular Institute, Fairfax, USA
-
show more...
-
Wojdyla, Daniel M (author)
-
- Wallentin, Lars, 1943- (author)
- Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),UCR
-
- Lewis, Basil S (author)
- The Ruth and Bruce Rappaport School of Medicine of the Technion, Haifa, Israel
-
- Verheugt, Freek W A (author)
- Onze Lieve Vrouwe Gasthuis (OLVG), Amsterdam, Netherlands
-
- Vinereanu, Dragos (author)
- University of Medicine and Pharmacy Carol Davila, University and Emergency Hospital of Bucharest, Bucharest, Romania
-
- Bahit, M Cecilia (author)
- INECO Neurociencias Oroño, Rosario, Argentina
-
- Halvorsen, Sigrun (author)
- University of Oslo, Oslo, Norway
-
- Huber, Kurt (author)
- Hospital and Sigmund Freud Private University, Medical School, Vienna, Austria
-
- Parkhomenko, Alexander (author)
- Institute of Cardiology, Kiev, Ukraine
-
Granger, Christopher B (author)
-
Lopes, Renato D (author)
-
Alexander, John H (author)
-
show less...
-
(creator_code:org_t)
- New York : Elsevier BV, 2018
- 2018
- English.
-
In: American Heart Journal. - New York : Elsevier BV. - 0002-8703 .- 1097-6744. ; 197, s. 133-141
- Related links:
-
https://urn.kb.se/re...
-
show more...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- BACKGROUND: We assessed antiplatelet therapy use and outcomes in patients undergoing percutaneous coronary intervention (PCI) during the ARISTOTLE trial.METHODS: Patients were categorized based on the occurrence of PCI during follow-up (median 1.8 years); PCI details and outcomes post-PCI are reported. Of the 18,201 trial participants, 316 (1.7%) underwent PCI (152 in apixaban group, 164 in warfarin group).RESULTS: inhibitor; 32% received antiplatelet agents without OAC. Post-PCI, patients assigned to apixaban versus warfarin had numerically similar rates of major bleeding (5.93 vs 6.73 events/100 patient-years; P = .95) and stroke (2.74 vs 1.84 events/100 patient-years; P = .62).CONCLUSIONS: PCI occurred infrequently during follow-up. Most patients on study drug at the time of PCI remained on study drug in the peri-PCI period; 19% continued the study drug without interruption. Antiplatelet therapy use post-PCI was variable, although most patients received DAPT. Additional data are needed to guide the use of antithrombotics in patients undergoing PCI.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Kopin, David
-
Jones, W Schuyle ...
-
Sherwood, Matthe ...
-
Wojdyla, Daniel ...
-
Wallentin, Lars, ...
-
Lewis, Basil S
-
show more...
-
Verheugt, Freek ...
-
Vinereanu, Drago ...
-
Bahit, M Cecilia
-
Halvorsen, Sigru ...
-
Huber, Kurt
-
Parkhomenko, Ale ...
-
Granger, Christo ...
-
Lopes, Renato D
-
Alexander, John ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cardiac and Card ...
- Articles in the publication
-
American Heart J ...
- By the university
-
Uppsala University